Abstract
Computer simulations within substrates that mimic the complexity of biological tissues are key to the development of biophysical diffusion Magnetic Resonance Imaging (dMRI) models. Realistic simulations have enabled, for example, the non-invasive estimation of fine neuronal sub-structures, which is playing an increasingly key role in neurology and neuro-science. However, biologically-realistic, simulation-informed dMRI techniques are also needed in other applications, as for example in oncological imaging of body tumours. This article aims to fill this gap by presenting a Monte Carlo (MC) framework tailored for histology-informed simulations in body imaging applications. The framework, which combines free software with custom-written routines, is demonstrated on substrates reconstructed from hematoxylin-eosin (HE) stains of human liver biopsies, including non-cancerous liver and primary/metastatic liver cancer tissues. The article has four main contributions. Firstly, it provides practical guidelines on how to conduct realistic MC diffusion simulations informed by HE histology. Secondly, it reports reference values on cell size (CS), cell density and on other cellular properties in non-cancerous and cancerous liver — information not easily found in the literature, yet essential to inform the design of innovative dMRI techniques. Thirdly, it presents a detailed characterisation of synthetic signals generated for clinically feasible dMRI protocols, shedding light onto patterns of intra-/extra-cellular (IC/EC) water diffusion in liver. Finally, it illustrates the utility of the framework, by devising a strategy where synthetic signals inform the estimation of unexplored microstructural properties, as the EC intrinsic diffusivity and CS distribution skewness. The strategy is demonstrated on actual dMRI scans, acquired on ex vivo mouse tissue and in cancer patients in vivo.
Competing Interest Statement
This study has received support by AstraZeneca. K.B. was a researcher at VHIO (Barcelona, Spain), and is now an employee of AstraZeneca (Barcelona, Spain). AstraZeneca was not involved in the acquisition and analysis of the data, interpretation of the results, or the decision to submit this article for publication in its current form.
Funding Statement
VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigacion) for the financial support as a Center of Excellence Severo Ochoa (CEX2020- 001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support on this research. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been cofunded by the European Regional Development Fund/European Social Fund 'A way to make Europe ' (to R.P.L.), and by the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI), funded by the Banco Bilbao Vizcaya Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L is supported by the "la Caixa " Foundation CaixaResearch Advanced Oncology Research Program, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019), the Asociacion Espanola Contra el Cancer (AECC) (PRYCO211023SERR) and the Generalitat de Catalunya Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). The project that gave rise to these results received the support of a fellowship from "la Caixa" Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010" (funding F.G, A.V., and A.G.). This research has received support from the Beatriu de Pinos Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586). The authors are thankful to the Vall d'Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance with MRI acquisitions, and to the GE/Siemens clinical scientists for their support with diffusion sequence characterisation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Clinical Research Ethics Committee (CEIm) of the Vall d'Hebron Hospital of Barcelona (Spain) gave ethical approval for the imaging study on cancer patients (approval code: PR(AG)29/2020). All participants to the study provide informed, written consent. All animal procedures were approved by the Animal Care unit and the Ethics Committee for Animal Experimentation (CEEA) of the Vall d'Hebron Research Institute (VHIR) and the Generalitat de Catalunya, and were performed according to the European legal framework for research animal use and bioethics.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵** joint senior (last) authors
Data Availability
The MC simulation framework is made freely available as a GitHub repository at the permanent address: https://github.com/radiomicsgroup/dMRIMC. The repository includes rich sets of synthetic signals that can be used to inform model fitting. The code for simulation-informed fitting is freely available as part of BodyMRITools at the permanent address: https://github.com/fragrussu/bodymritools (script mri2micro_dictml.py). The ex vivo mouse data will be soon released on the Radiomics Group GitHub web site (https://radiomicsgroup.github.io/data). Researchers interested in early access can contact the corresponding author Raquel Perez-Lopez (rperez{at}vhio.net). The in vivo human data cannot be made freely available at this stage due to ethical restrictions.
